Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
SAB Biotherapeutics (SABS) has provided an update.
SAB Biotherapeutics, Inc. has appointed Dr. Jay S. Skyler as a Class I director, effective May 3, 2024. With no disclosed conflicts of interest or familial ties to the company’s current leadership, Dr. Skyler brings a wealth of experience from his medical and academic career, including significant roles in diabetes research and positions on the boards of various public companies. His expertise is expected to be a valuable asset to the board, reflecting his distinguished career in the life sciences sector.
Find detailed analytics on SABS stock on TipRanks’ Stock Analysis page.